Savara Inc.
SVRAHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Savara Inc. focuses on Biotechnology services and products. Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases in the United States. The company carries a $1.19B market cap, placing it firmly in the small-cap category. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis.
Market Cap
$1.19B
Beta
0.24
P/E (TTM)
—
P/E (Fwd)
-19.76
EPS (TTM)
$-0.57
EPS (Fwd)
$-0.29
ROE
-80.0%
ROA
-40.5%
Cash
$204.1M
Total Debt
$30.1M
Free CF
-$57.7M
52W Change
151.5%
Annual Financials
Cash vs Debt
With $204.1M in cash and $30.1M in debt, SVRA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$57.7M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. ROE of -80.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity.
SVRA's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. No single metric tells the full story. Reviewing SVRA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.